Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2013;63:11–30
   PubMed Web of Science ®Google Scholar
• Olson WC, Heston WDW, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials 2007;2:182–90
   PubMedGoogle Scholar
• Siegel R, Desantis C, Virgo K, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin 2012;62:220–41
   PubMed Web of Science ®Google Scholar
• Tannock IF, Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12
   PubMed Web of Science ®Google Scholar
• Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Disc 2008;7:771–82
   PubMed Web of Science ®Google Scholar
• Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006;6:688–701
   PubMed Web of Science ®Google Scholar
• Kopeček J. Polymer–drug conjugates: origins, progress to date and future directions. Adv Drug Delivery Rev 2013;65:49–59
   PubMed Web of Science ®Google Scholar
• Kopeček J, Kopečková P. Design of polymer-drug conjugates. In: Kratz F, Senter P, Steinhagen H, eds. Drug delivery in oncology, Vol. 2, Chapter 17. Weinheim, Germany: Wiley-VCH; 2012:485–512
   Google Scholar
• Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2012;2:3–44
   PubMed Web of Science ®Google Scholar
• Zhou Y, Kopeček J. Biological rationale for the design of polymeric anticancer nanomedicines. J Drug Target 2013;21:1–26
   PubMed Web of Science ®Google Scholar
• Schulke N, Varlamova OA, Donovan GP, et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci USA 2003;100:12590–5
   PubMed Web of Science ®Google Scholar
• Israeli, RS, Powell CT, Corr JG, et al. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:1807–11
   PubMed Web of Science ®Google Scholar
• Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004;91:528–39
   PubMed Web of Science ®Google Scholar
• Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003;9:6357–62
   PubMed Web of Science ®Google Scholar
• Ni X, Zhang Y, Ribas J, et al. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest 2011;121:2383–90
   Google Scholar
• Dassie JP, Liu XY, Thomas GS, et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 2009;27:839–46
   PubMed Web of Science ®Google Scholar
• Bagalkot V, Farokhzad OC, Langer R, Jon S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed 2006;45:8149–52
   PubMed Web of Science ®Google Scholar
• Elsässer-Beile U, Reischl G, Wiehr S, et al. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med 2009;50:606–11
   PubMed Web of Science ®Google Scholar
• Evans MJ, Smith-Jones PM, Wongvipat J, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci USA 2011;108:9578–82
   PubMed Web of Science ®Google Scholar
• Henry MD, Wen S, Silva MD, et al. A prostate-specific membrane antigen targeted monoclonal antibody chemotherapeutic conjugates designed for the treatment of prostate cancer. Cancer Res 2004;64:7995–8001
   PubMed Web of Science ®Google Scholar
• Moffatt S, Papasakelariou C, Wiehle S, Cristiano R. Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate. Gene Therapy 2006;13:761–72
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Singh P, Topaloglu O, et al. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res 2006;66:9171–7
   PubMed Web of Science ®Google Scholar
• Rege K, Patel SJ, Megeed Z, Yarmush ML. Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells. Cancer Res 2007;67:6368–75
   PubMed Web of Science ®Google Scholar
• Kularatne SA, Wang K, Santhapuram HKR, Low PS. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharmaceutics 2009;6:780–9
   PubMed Web of Science ®Google Scholar
• Kularatne SA, Venkatesh C, Santhapuram HKR, et al. Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs. J Med Chem 2010;53:7767–77
   PubMed Web of Science ®Google Scholar
• Sanna V, Pintus G, Bandiera P, et al. Development of polymeric microbubbles targeted to prostate-specific membrane antigen as prototype of novel untrasound contrast agents. Mol Pharmaceutics 2011;8:748–57
   PubMed Web of Science ®Google Scholar
• Banerjee SR, Pullambhatla M, Byun Y, et al. Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angew Chem Int Ed 2011;50:9167–70
   PubMed Web of Science ®Google Scholar
• Humblet V, Misra P, Bhushan KR, et al. Multivalent scaffolds for affinity maturation of small molecule cell surface binders and their application to prostate tumor targeting. J Med Chem 2009;52:544–50
   PubMed Web of Science ®Google Scholar
• Maresca KP, Hillier SM, Femia FJ, et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem 2009;52:347–57
   PubMed Web of Science ®Google Scholar
• Liu T, Nedrow-Byers JR, Hopkins MR, Berkman CE. Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitor of prostate specific membrane antigen. Bioorg Med Chem 2011;21:7013–16
   Web of Science ®Google Scholar
• Zhou J, Neale JH, Pomper MG, Kozikowski AP. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Disc 2005;4:1015–25
   PubMed Web of Science ®Google Scholar
• Jayaprakash S, Wang X, Heston WD, Kozikowski AP. Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy. ChemMedChem 2006;1:299–302
   PubMed Web of Science ®Google Scholar
• Zhang AX, Murelli RP, Barinka C, et al. A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc 2010;132:12711–16
   PubMed Web of Science ®Google Scholar
• Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci USA 2005;102:5981–6
   PubMed Web of Science ®Google Scholar
• Mesters JR, Barinka C, Li W, et al. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J 2006;25:1375–84
   PubMed Web of Science ®Google Scholar
• Kopeček J, Kopečková, P. HPMA copolymers: origins, early developments, present, and future. Adv Drug Delivery Rev 2010;62:122–49
   PubMed Web of Science ®Google Scholar
• Kopeček J, Bažilová H. Poly[N-(2-hydroxypropyl)methacrylamide]. 1. Radical polymerization and copolymerization. Eur Polym J 1973;9:7–14
   Web of Science ®Google Scholar
• Rejmanová P, Pohl J, Baudyš M, et al. Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol Chem 1983;184:2009–20
   Web of Science ®Google Scholar
• Mitsukami Y, Donovan MS, Lowe AB, McCormick CL. Water-soluble polymers. 81. Direct synthesis of hydrophilic styrenic-based homopolymers and block copolymers in aqueous solution via RAFT. Macromolecules 2001;34:2248–56
   Web of Science ®Google Scholar
• Satchi-Fainaro R, Puder M, Davies JW, et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 2004;10:255–61
   PubMed Web of Science ®Google Scholar
• Liu J, Kopečková, P, Pan H, et al. Prostate cancer targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates. Macromol Biosci 2012;12:412–22
   PubMed Web of Science ®Google Scholar
• York AW, Kirkland SE, McCormick CL. Advances in the synthesis of amphiphilic block copolymers via RAFT polymerization: stimuli-responsive drug and gene delivery. Adv Drug Delivery Rev 2008;60:1018–36
   PubMed Web of Science ®Google Scholar
• Etrych T, Šírová M, Starovoytova L, et al. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release. Mol Pharmaceutics 2010;7:1015–26
   PubMed Web of Science ®Google Scholar
• Thaimann GN, Anezinis PE, Chang SM, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577–81
   PubMed Web of Science ®Google Scholar